Gengwei Huo

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Endometrial Cancer

Small Cell Lung Cancer

Health Insurance

Radiation Therapy

Top Venues

Journal of gynecologic oncology

Translational lung cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Gengwei Huo, Ying Song, Xiongwen Chen, Peng Chen
Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis. Translational lung cancer research 13 (4) (2024)
Gengwei Huo, Ying Song, Xiongwen Chen, Peng Chen
Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis. Translational lung cancer research 13 (4) (2024)
Gengwei Huo, Ying Song, Peng Chen
Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer. Journal of gynecologic oncology (2024)
Gengwei Huo, Ying Song, Peng Chen
Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer. Journal of gynecologic oncology (2024)
Gengwei Huo, Wenjie Liu, Peng Chen
Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer. Journal of gynecologic oncology (2024)